In silico analysis of the prognostic value of FAS mRNA in malignancies

Chen, Zhigang; Wu, Jun; Xu, Hailin; Yu, Xijie; Wang, Ke

doi:10.7150/jca.35614

Cited by 4 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, they found that relapse-free survival was prolonged in FAS-positive cases compared to FAS negative ones ( 4 ). In addition, Chen et al, evaluating the prognostic value of FAS mRNA in various malignancies using online platforms, reported that higher expression of FAS was related to a poorer OS in AML patients (Hazard ratio, 1.57; P = 0.04) ( 10 ).…”

Section: Discussionmentioning

confidence: 99%

Expression of DR4, DR5, FAS, Caspase-8 and, DDIAS Genes in AML Patients

Naghinezhad,

Alenabi,

Ayatollahi

et al. 2023

MJIRI

View full text Add to dashboard Cite

Background Acute myeloid leukemia (AML) is the most common acute leukemia in adults and accompanies a worse survival. In this study, gene expression levels of 5 key players of apoptosis, including DR4, DR5, FAS, caspase 8, and DNA damage-induced apoptosis suppressor (DDIAS), have been evaluated in AML patients compared with controls, aiming to evaluate their possible role and prognostic impact. Methods This cross-sectional study was performed in the Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences. A total of 30 newly diagnosed AML cases as well as 30 healthy controls enrolled in the study. Real-time polymerase chain reaction was used to evaluate the expressions of DR4, DR5, FAS, DDIAS, and caspase 8 genes in cases and controls. Other necessary data, including cytogenetic findings, mutations, French-American-British (FAB) classification, and survival, were retrieved from hospital records and by direct contact with patients. Statistical analysis was done by SPSS software. When appropriate, the Mann-Whitney U, Pearson's correlation, and the t tests were utilized. Overall survival (OS) was estimated using the Kaplan-Meier method. Results The expression of all evaluated genes, including DDIAS (0.89 ± 0.20), DR4 (0.67 ± 0.24), DR5 (0.72 ± 0.24), FAS (0.70 ± 0.25), and Caspase 8 (0.77 ± 0.20) were significantly decreased in AML patients compared with the controls ( P < 0.001). Patients with the t (16;16) or inv (16) expressed significantly higher amounts of the FAS gene and those with FLT3 mutation exhibited lower expression of caspase 8. Expression of the evaluated genes showed no significant effect on survival. Conclusion The expression of DR4, DR5, FAS, and caspase 8 seems to be decreased in AML. Lower expression of these molecules may aid AML cells in avoiding apoptosis because they are involved in the initiation of apoptosis, making them potential targets for treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of DR4, DR5, FAS, Caspase-8 and, DDIAS Genes in AML Patients

Naghinezhad,

Alenabi,

Ayatollahi

et al. 2023

MJIRI

View full text Add to dashboard Cite

show abstract

“…FAS and GADD45A have been reported to play a role in inducing apoptosis and have also been previously identified to have a positive correlation with patient prognosis in patients with NSCLC. [59][60][61][62][63] DPYSL4 has been reported to function as a tumor suppressor, 64 and interestingly, DPYSL4 has also been reported to play a role in inducing necrosis. 65 However, necrosis was not an area of focus for this study, and 5-FU-miR-129's role in necrosis can be examined in future studies.…”

Section: Discussionmentioning

confidence: 99%

Development of a 5-FU Modified miR-129 Mimic as a Therapeutic for Non-Small Cell Lung Cancer

Hwang

Yuen

Fesler³

et al. 2022

Preprint

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related deaths in the United States with non-small cell lung cancer (NSCLC) accounting for most cases. Despite advances in cancer therapeutics, the 5-year survival rate has remained poor due to several contributing factors, including its resistance to therapeutics. Therefore, there is a pressing need to develop therapeutics that can overcome resistance. Non-coding RNAs, including microRNAs (miRNAs), have been found to contribute to cancer resistance and therapeutics by modulating the expression of several targets involving multiple key mechanisms. In this study, we investigated the therapeutic potential of miR-129 modified with 5-fluorouracil (5-FU) in NSCLC. Our results show that 5-FU modified miR-129 (5-FU-miR-129) inhibits proliferation, induces apoptosis, and retains function as a miRNA in NSCLC cell lines A549 and Calu-1. Notably, we observed that 5-FU-miR-129 was able to overcome resistance to tyrosine kinase inhibitors and chemotherapy in cell lines resistant to erlotinib or 5-FU. Furthermore, we observed that the inhibitory effect of 5-FU-miR-129 can also be achieved in NSCLC cells under vehicle-free conditions. Finally, 5-FU-miR-129 inhibited NSCLC tumor growth and extended survival in vivo without toxic side effects. Altogether, our results demonstrate the potential of 5-FU-miR-129 as a highly potent cancer therapeutic in NSCLC.

show abstract

“…RBM10 can regulate the selective cleavage of Fas transcripts ( 28 ). Fas is a classical death receptor involved in the Fas/Fas ligand (FasL) apoptosis pathway, which has anti-tumor activity ( 29 ), and can cause cascade reactions that lead to cell death. Fas is a pro-apoptotic protein that produces pro-apoptotic subtypes and anti-apoptotic subtypes through alternative splicing ( 30 ).…”

Section: Roles Of Rna-binding Motif Protein 10 In Regulating Tumor Dementioning

confidence: 99%

RBM10 Regulates Tumor Apoptosis, Proliferation, and Metastasis

Cao

Zhang

et al. 2021

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

The RNA-binding motif protein 10 (RBM10) is involved in alternative splicing and modifies mRNA post-transcriptionally. RBM10 is abnormally expressed in the lung, breast, and colorectal cancer, female genital tumors, osteosarcoma, and other malignant tumors. It can inhibit proliferation, promote apoptosis, and inhibit invasion and metastasis. RBM10 has long been considered a tumor suppressor because it promotes apoptosis through the regulation of the MDM2-p53 negative feedback loop, Bcl-2, Bax, and other apoptotic proteins and inhibits proliferation through the Notch signaling and rap1a/Akt/CREB pathways. However, it has been recently demonstrated that RBM10 can also promote cancer. Given these different views, it is necessary to summarize the research progress of RBM10 in various fields to reasonably analyze the underlying molecular mechanisms, and provide new ideas and directions for the clinical research of RBM10 in various cancer types. In this review, we provide a new perspective on the reasons for these opposing effects on cancer biology, molecular mechanisms, research progress, and clinical value of RBM10.

show abstract

In silico analysis of the prognostic value of FAS mRNA in malignancies

Cited by 4 publications

References 35 publications

Expression of DR4, DR5, FAS, Caspase-8 and, DDIAS Genes in AML Patients

Expression of DR4, DR5, FAS, Caspase-8 and, DDIAS Genes in AML Patients

Development of a 5-FU Modified miR-129 Mimic as a Therapeutic for Non-Small Cell Lung Cancer

RBM10 Regulates Tumor Apoptosis, Proliferation, and Metastasis

Contact Info

Product

Resources

About